Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7 TCR T Cell Induction Immunotherapy for Cervical Cancer
NCT04476251Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2021
- Primary completion
- Sep 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KITE-439 in Cervical Cancer (CC), sponsored by National Cancer Institute. Primary endpoint: Fraction of Participants for Whom E7 TCR Induction Therapy is Feasible at 6 months. Started Jan 2021; status: terminated.
02
Drugs
KITE-439
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04476251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04476251.